PriceTargets.com logo

Genenta Science - GNTA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 398.01%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.02 As of 11/15/2024 01:00 AM ET
▲ +0.13 (2.66%)

This chart shows the closing price for GNTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genenta Science Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNTA

Analyst Price Target is $25.00
▲ +398.01% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Genenta Science in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 398.01% upside from the last price of $5.02.

This chart shows the closing price for GNTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Genenta Science. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00
6/29/2023Roth CapitalReiterated RatingBuy
2/8/2023HC WainwrightReiterated RatingBuy$25.00
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$15.00
7/25/2022HC WainwrightInitiated CoverageBuy$25.00
1/13/2022Maxim GroupInitiated CoverageBuy$21.00
1/12/2022Roth CapitalReiterated RatingBuy
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Genenta Science logo
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Read More

Today's Range

Now: $5.02
Low: $4.81
High: $5.20

50 Day Range

MA: $4.77
Low: $3.30
High: $6.92

52 Week Range

Now: $5.02
Low: $2.20
High: $7.28

Volume

6,439 shs

Average Volume

11,285 shs

Market Capitalization

$91.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Genenta Science?

The following Wall Street analysts have issued reports on Genenta Science in the last year: HC Wainwright.
View the latest analyst ratings for GNTA.

What is the current price target for Genenta Science?

0 Wall Street analysts have set twelve-month price targets for Genenta Science in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 398.0%. HC Wainwright has the highest price target set, predicting GNTA will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $25.00 for Genenta Science in the next year.
View the latest price targets for GNTA.

What is the current consensus analyst rating for Genenta Science?

Genenta Science currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GNTA will outperform the market and that investors should add to their positions of Genenta Science.
View the latest ratings for GNTA.

What other companies compete with Genenta Science?

Other companies that are similar to Genenta Science include Sage Therapeutics, COMPASS Pathways, YS Biopharma, Alpha Teknova and iTeos Therapeutics. Learn More about companies similar to Genenta Science.

How do I contact Genenta Science's investor relations team?

The company's listed phone number is 39-02-2643-4681 and its investor relations email address is [email protected]. The official website for Genenta Science is www.genenta.com. Learn More about contacing Genenta Science investor relations.